-
2022-500138-27-01
5
2023-02-28
Multiple Myeloma
-
2024-511594-30-00
5
2023-02-23
Relapsed/Refractory Follicular Lymphoma
-
2022-501493-19-00
5
2023-02-20
metastatic Castration-Resistant Prostate Cancer (mCRPC)
-
2024-514147-28-00
5
2022-12-02
Primary immune thrombocytopenia
-
2023-508869-32-00
5
2022-11-10
Cancer - Plasma cell myeloma recurrent
-
2023-505628-67-00
5
2022-10-28
Relapsed and Refractory Follicular Lymphoma
-
2024-514394-22-00
6
2022-10-24
Actinic Keratosis
-
2024-517008-12-00
5
2022-10-14
Newly-diagnosed multiple myeloma (NDMM)
-
2023-503467-41-00
5
2022-10-12
Relapsed or Refractory Multiple Myeloma
-
2024-518870-15-00
4
2022-10-03
Multiple Myeloma
-
2023-509657-31-00
5
2022-08-24
Paroxysmal nocturnal haemoglobinuria (PNH)
-
2024-511126-31-00
5
2022-08-16
Non-obstructive Coronary Artery Disease
-
2024-514630-21-00
4
2022-08-11
HER2 positive (HER2+), Hormone Receptor positive (HR+) Early-stage Bre
-
2022-502681-24-00
3
2022-06-22
Relapsed or Refractory Multiple Myeloma
-
2024-510800-35-00
5
2022-06-17
Relapsed or Refractory Multiple Myeloma (RRMM)
-
2024-516294-78-00
4
2022-06-17
Acute Myeloid Leukemia (AML)
-
2024-514723-42-00
9
2022-05-05
Locally advanced unresectable or metastatic, microsatellite instabilit
-
2023-507469-24-00
4
2022-04-30
Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodyspl
-
2023-507069-25-00
4
2022-04-29
Amyloid Light Chain Amyloidosis
-
2023-508897-27-00
5
2022-04-28
Multiple Myeloma
-
2023-507468-38-00
4
2022-04-22
Myelofibrosis
-
2023-503640-14-00
5
2022-02-17
Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphobla
-
2024-515069-33-00
5
2022-02-15
Patients with anemia due to IPSS-R defined very low-, low-, or interme
-
2023-503826-37-00
5
2022-02-11
Unresectable locally-advanced or metastatic HER2+ breast cancer